UFT Plus Vinorelbine in Advanced Non-small Cell Lung Cancer: A Phase I and an Elderly Patient-Directed Phase II Study  by Igishi, Tadashi et al.
ORIGINAL ARTICLE
UFT Plus Vinorelbine in Advanced Non-small Cell
Lung Cancer
A Phase I and an Elderly Patient-Directed Phase II Study
Tadashi Igishi, MD, PhD,*† Yasushi Shigeoka, MD, PhD,*† Kazuhito Yasuda, MD, PhD,*†
Hisashi Suyama, MD, PhD,*† Satoru Katayama, MD, PhD,† Akinori Sugitani, MD,†
Shingo Matsumoto, MD, PhD,*† Mitsunobu Yamamoto, MD, PhD,†
Yasuto Ueda, MD,*† Kenichi Takeda, MD, PhD,*† Takashi Sumikawa, MD, PhD,*†
Takanori Sako, MD, PhD,*† Masahiro Kodani, MD, PhD,*† Yutaka Hitsuda, MD, PhD,*†
and Eiji Shimizu, MD, PhD*†
Purpose: The combination of tegafur-uracil (UFT) with vinorelbine
has provided synergistic activity against non-small cell lung cancer
(NSCLC) in experimental models. The recommended dose of UFT
in combination with vinorelbine in NSCLC was determined in a
phase I study. The phase II study evaluated efficacy and tolerability
of this combination in elderly patients.
Methods: Vinorelbine was infused on days 1 and 8, and UFT was
administered twice daily on days 2 to 6 and days 9 to 13 of a 3-week
cycle. UFT and vinorelbine were increased during the phase I study
from 400 to 600 mg/d and 20 to 25 mg/m2, respectively, in 12
patients. In the phase II portion, previously untreated elderly patients
were treated with 600 mg/d UFT and 20 mg/m2 vinorelbine.
Results: At the dose level of 600 mg/d UFT and 25 mg/m2
vinorelbine, dose-limiting toxicity of neutropenia or neutropenic
fever was observed in two of three patients, determining the recom-
mended dose of 600 mg/d UFT and 20 mg/m2 vinorelbine. In 30
evaluable elderly patients of the phase II study, the response rate was
27% (8/30). The median survival and progression-free survival time
was 11.8 (range 2.7–34.8) and 5.0 (range 0.5–32.5) months, respec-
tively. Grade 3 or grade 4 neutropenia and grade 3 anemia occurred
in 40% and 7% of phase II patients, respectively. Gastrointestinal
toxicity was frequent but mild. As the most serious toxicity, pneu-
monitis was observed in three patients.
Conclusion: This combination of UFT and vinorelbine is both
feasible and active in the treatment of elderly patients with advanced
NSCLC.
Key Words: UFT, Vinorelbine, Non-small cell lung cancer, Phase
I and phase II study, Elderly patient.
(J Thorac Oncol. 2009;4: 376–382)
Systemic chemotherapy for patients with advanced-stagenon-small cell lung cancer (NSCLC) prolongs survival
and palliates symptoms compared with the best supportive
care alone. Meta-analysis of patients with advanced NSCLC
treated with cisplatin-based therapy shows a slight improve-
ment of 1.5 months in median survival time (MST).1 Third-
generation agents (taxane, gemcitabine, vinorelbine, irinote-
can) became available, and each has shown good single-agent
activity against NSCLC.2 In general, the combination of
cisplatin with such agents is considered to be standard che-
motherapy for advanced NSCLC.3 However, the toxicity of
platinum-based chemotherapy is generally higher than that of
nonplatinum-based treatment, and 1-year survival is not sig-
nificantly prolonged when platinum-based therapies are com-
pared with new agent-based combination regimens.4 Accord-
ingly, nonplatinum-based chemotherapy can be an option for
elderly patients, those with a poor performance status (PS),
and outpatients.
In this context, vinorelbine is an attractive candidate for
nonplatinum-based combination chemotherapy, because this
agent is one of the standard medical treatments for elderly
patients with NSCLC.5–7
Tegafur-uracil (UFT) is an oral anticancer agent that
combines tegafur and uracil at a molar ratio of 1:4. Tegafur is
a prodrug of 5-fluorouracil (5-FU), and uracil is a competitive
and reversible inhibitor of dihydropyrimidine dehydrogenase
(DPD), the rate-limiting enzyme responsible for the catabo-
lism of 5-FU. Thus, UFT is referred to as DPD inhibitory
fluoropyrimidine.8 The effectiveness of UFT has been re-
ported in several cancers, especially in those arising in the
gastrointestinal tract.9,10 Although the usefulness of UFT has
not yet been established in the treatment of advanced
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NSCLC, several recent reports indicate that the long-term
administration of UFT is effective in prolonging the survival
of patients with NSCLC after surgical resection,11–13 suggest-
ing the potential of UFT as a chemotherapeutic agent for
advanced NSCLC. Furthermore, recent several phase II clin-
ical trials in advanced NSCLC have shown good response
rates (RRs) when UFT was combined with cisplatin or
gemcitabin.14–17
Our preclinical data suggest that vinorelbine injection
before oral UFT administration may provide synergistic ac-
tivity against NSCLC in vitro and in an animal model.18
Thus, we conducted a phase I dose-escalation trial to deter-
mine the maximum tolerated dose (MTD) and recommended
doses of oral UFT/vinorelbine and a phase II study to assess
the activity and tolerability of this combination therapy in
elderly patients with locally advanced or metastatic NSCLC.
PATIENTS AND METHODS
Patient Eligibility
To participate in the present trial, patients were re-
quired to have histologically or cytologically confirmed
NSCLC with measurable progressive regional or metastatic
disease. They also had to be 20 years of age or older in the
phase I study or 70 years or older in the phase II study and
have a PS of 0 or 1 on the Eastern Cooperative Oncology
Group scale19 and an estimated life expectancy of at least 12
weeks. Phase I patients could receive other cancer therapy up
to 4 weeks before enrollment, whereas phase II patients were
required to have received no prior therapy.
Required laboratory results included adequate baseline
organ function, defined as a white blood cell (WBC) count of
at least 4000/mm3, a neutrophil count of at least 2000/mm3,
a platelet count of at least 100,000/ mm3, a bilirubin level of
less than 1.5 mg/dL, serum aspartate aminotransferase/ala-
nine transaminase levels of less than 2.5 times the upper
normal limit, and a creatinine value of less than 1.5 mg/dL.
Pretreatment evaluation included electrocardiogram, chest
x-ray, respiratory tests, bronchoscopy, and computed tomog-
raphy of the chest and upper abdomen. Radionuclide scans of
bone and computed tomography scans of the brain were also
performed as necessary to document the extent of the disease.
All patients gave written informed consent for study partici-
pation. This study was approved by the institutional review
board of Tottori University.
Treatment Plan
Vinorelbine was infused on days 1 and 8, and UFT was
administered orally in two divided doses each day from day
2 to day 6 and from day 9 to day 13 of a 3-week cycle. The
starting doses of vinorelbine and UFT were 20 mg/m2 and
400 mg/d, respectively. Both drugs were escalated according
to a preestablished schedule in the phase I study (Table 1).
In the phase II study, 20 mg/m2 vinorelbine on days 1
and 8, and 600 mg/d UFT on days 2 to 6 and days 9 to 13
were administered in a 3-week cycle, respectively, based on
the recommended dose determined in the phase I study. At
any cycle, the administration of both vinorelbine and UFT
were postponed if patients met any of the following criteria:
WBC 2000/mm3; neutrophils 1000/mm3; platelets
50,000/mm3; active infection; grade 2 or worse nonhema-
tologic toxicity, except for nausea, vomiting, anorexia, fa-
tigue, or alopecia. During a cycle, day-8 vinorelbine and the
following UFT were postponed until day 15 if the WBC
count was less than 2000/mm3 on day 8. In the case of grade
2 or more severe anorexia, the dose of UFT was reduced from
600 to 400 mg/d. If patients could not satisfy the above-
mentioned criteria to start a new cycle after a 7-day delay,
WBC count was less than 2000/mm3 on day 15, or grade 2 or
worse anorexia continued after the dose reduction of UFT,
the patient would be withdrawn from the study. The treatment
was continued in the absence of progressive disease or
intolerable toxicity.
Maximum Tolerated Dose
In the phase I study, at least three patients were enrolled
at each dose level. We defined MTD as the dose causing
dose-limiting toxicity (DLT) in 50% rather than in 33% to
reduce the risk of insufficient drug administration. If none of
the three patients showed symptoms of DLT during cycle 1 or
2, the dose was escalated to the next level. If one of three
showed DLT, then three additional patients were treated at
the same dose level, and further escalation was permitted if
fewer than three of six showed DLT. If two or more out of a
cohort of three, or three or more out of a cohort of six patients
displayed DLT, no further dose escalation would take place,
and the level was declared the MTD. The preceding dose
level would be deemed to be the recommended dose level.
DLT was defined as grade 4 leukocytopenia, grade 4 neutro-
penia over 3 days, fever with grade 4 neutropenia, grade 4
thrombocytopenia, or grade 3 or higher nonhematologic tox-
icity (excluding nausea and vomiting, anorexia, fatigue, and
alopecia). Toxicity evaluations were based on the National
Cancer Institute’s common toxicity criteria (version 2).
Response
We performed tumor reassessment after each course of
therapy using the same imaging method used for baseline
tumor measurement. Tumor response was assessed according
to the Response Evaluation Criteria in Solid Tumors.20 Ob-
jective responses required confirmation by a subsequent re-
sponse evaluation separated by at least 4 weeks.
Statistical Consideration
The primary end point of the phase II study was the
overall RR. According to Fleming’s21 single stage procedure,
with a sample size of n  29, our study had 80% power to
accept the hypothesis that true RR was greater than 40% and
5% significance (one tailed) to reject the hypothesis that true
RR was less than 20%. Estimating a dropout of six patients,
TABLE 1. Dose-Escalation Scheme
Level Vinorelbine (mg/m2; d 1, 8) UFT (mg/d; d 2–6, d 9–13)
I 20 400
II 20 600
III 25 600
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a total of 35 patients were recruited to the phase II study to
ensure at least 29 patients were evaluable. We evaluated
survival, toxicity, and time to progression as secondary end
points. Survival and time to progression were calculated
using the Kaplan-Meier method.
RESULTS
Patient Characteristics
The characteristics of the patient population are listed
in Table 2. A total of 12 patients were enrolled in the phase
I study between June 2002 and March 2003, whereas 35
patients were enrolled in the phase II study between June
2003 and March 2006. Five patients in phase II were ex-
cluded from analysis because of consent withdrawal (one
case), poor PS at the enrollment because of compressed
fracture of the lumbar spine and unexplained fever (two
cases, fulfillment of protocol exclusion criteria), and proceed-
ing radiotherapy before the enrollment (two cases, protocol
violation). These patients did not receive any trial treatment.
In the phase I study, there were three patients with stage
IIIB disease and nine with stage IV disease. Nine patients had
had no previous chemotherapy. In six patients with no pre-
vious treatment, one, four, and one patients were assigned to
dose level I, II, and III, respectively. A total of 52 cycles of
chemotherapy were administered to phase I subjects, with
a median number of cycles per patient of 4.3 (range 2–20).
All patients were assessable for toxicity and response to
treatment.
In the phase II study, six previously untreated patients
were in stage IIIB (20%) and 24 were in stage IV (80%) with
a median age of 78 years (range 71–86). Four patients had
squamous cell carcinoma (14%), 25 adenocarcinoma (83%),
and one unclassified NSCLC (3%). A total of 232 cycles of
chemotherapy were administered to phase II patients with a
median number of cycles per patient of 4 (range 1–46).
Thirty patients were assessable for toxicity and response to
treatment.
Phase I Study
Hematological toxicity
No DLT was observed at dose level I. At dose level II,
one of three patients had grade 4 neutropenia with fever
(DLT), and three patients were then added at this level. Grade
4 neutropenia over 3 days (DLT) was observed in one of three
additional patients. Although one patient had grade 4 neutro-
penia, the duration of this toxicity was 2 days. We progressed
to dose level III, at which DLT was observed in two of three
patients (Table 3). DLT appeared as severe neutropenia or
neutropenia with fever, and the MTD was determined to be
level III. Therefore, the recommended tolerable dose for
phase II trials was dose level II.
Nonhematological toxicity
No nonhematological DLT was observed in the first
two cycles of any patient. Details of toxicity for all cycles are
shown in Table 3. Although no nausea or vomiting occurred,
anorexia was the most frequent adverse effect. At dose levels
I and III, grade 1 anorexia occurred in one patient; at dose
level II, grade 1 anorexia was observed in two patients, and
grade 3 anorexia was observed in one patient. Injection site
reaction occurred in two patients at level I and in one patient
at level III. Grade 2 pneumonitis occurred in one patient at
level II. No lethal toxicity was observed at any level.
Antitumor activity
Of the 12 patients treated, three (25%) showed a partial
response, six (50%) had stable disease, and three (25%) had
progressive disease. In six patients with no previous treat-
ment, two, three, and one patients showed a partial response,
stable disease, and progressive disease, respectively.
Phase II Study
Treatment delivery
Thirty elderly patients with a median age of 78 years
were treated in the phase II study. In 54 of a total of 232
cycles (23%), day-8 vinorelbine and the following UFT or the
start of a new cycle was delayed for 7 days. The most
common cause for the delay was leukopenia or neutropenia
(48 cycles). Dose reduction of UFT from 600 to 400 mg/d
was performed in nine patients (eight patients because of
anorexia; one patient because of diarrhea). The relative mean
dose-intensity of the planned dose was 90% for vinorelbine
and 78% for UFT.
TABLE 2. Patient Characteristics
Phase I (n  12) Phase II (n  30)
Age (yr)
Median (range) 69 (53–81) 78 (71–86)
Gender (%)
Male 10 (83) 20 (67)
Female 2 (17) 10 (33)
ECOG performance status (%)
0 2 (17) 14 (47)
1 10 (83) 16 (53)
Histology (%)
Squamous 7 (58) 4 (14)
Adenocarcinoma 5 (42) 25 (83)
Other 0 1 (3)
Stage (%)
IIIB 3 (25) 6 (20)
IV 9 (75) 24 (80)
Previous treatment (%)
None 6 (50) 30 (100)
Radiotherapy 5 (42) 0
Platinum-based chemotherapy 2 (17) 0
Nonplatinum-based
chemotherapy
1 (8) 0
Smoking history (%)
Never smoked 1 (8) 11 (37)
Current or exsmoker 11 (92) 19 (63)
Igishi et al. Journal of Thoracic Oncology • Volume 4, Number 3, March 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer378
Efficacy
Among 30 assessable patients, eight patients achieved
partial response, whereas no complete response was ob-
served, yielding an overall RR of 27% (90% confidence
interval, 13–40%). Stable disease was observed in 18 of the
30 patients.
July 24, 2007, was the cutoff date for updating survival.
The median survival was 11.8 months (range 2.7–34.8
months), and the median progression-free survival was 5.0
months (range 0.5–32.5 months) (Figure 1).
Toxicity
Thirty patients in the phase II study were assessable for
toxicity. Hematologic toxicity was common, as shown in
Table 4. Grade 3 leukopenia occurred in six patients (20%),
and grade 3 or grade 4 neutropenia occurred in 12 patients
(40%). However, febrile neutropenia developed in only two
patients (7%). Grade 3 anemia was observed in two patients
(7%). No grade 3 or grade 4 thrombocytopenia was noted. No
patient discontinued the trial because of hematologic toxicity.
Nonhematologic toxicity in the phase II study is sum-
marized in Table 4. The most common adverse effect was
gastrointestinal toxicity such as anorexia and constipation. In
general, these toxicities were mild and well tolerated after the
dose reduction of UFT from 600 to 400 mg/d or proper
medication.
The most serious toxicity was pneumonitis, which was
observed in three patients (10%). Among them, the drug-
FIGURE 1. Kaplan-Meier analysis of overall survival and progression-free survival. Median overall survival time  11.8
months. Median progression-free survival time  5.0 months.
TABLE 3. Toxicity in Phase I Study
Toxicity
NCI-CTC Grade
Level I (n  3) Level II (n  6) Level III (n  3)
1 2 3 4 1 2 3 4 1 2 3 4
Hematologic toxicity
Leukopenia 1 0 0 0 2 1 3 0 0 0 3 0
Neutropenia 0 1 0 0 1 1 0 3b 0 1 0 2a
Febrile neutropenia — — 0 0 — — 1a 0 — — 2b 0
Anemia 1 0 0 0 3 0 0 0 2 0 0 0
Thrombocytopenia 0 1 0 0 0 1 0 0 0 1 0 0
Nonhematologic toxicity
Increase in AST 1 0 0 0 1 0 0 0 0 0 0 0
Increase in ALT 1 0 0 0 1 0 0 0 0 0 0 0
Increase in Cr 0 0 0 0 0 0 0 0 1 0 0 0
Anorexia 1 0 0 0 2 0 1 0 1 0 0 0
Constipation 1 0 0 0 1 1 0 0 — 0 0
Injection site reaction 1 1 0 — 0 0 0 — 0 1 0 —
Pneumonitis 0 0 0 0 0 1 0 0 0 0 0 0
a One and b two patients experienced dose limiting toxicity.
NCI-CTC, National Cancer Institute Common Toxicity Criteria; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Cr, creatinine.
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induced lymphocyte stimulation test22 for UFT was positive
in one case. All of them recovered from this complication
after oxygen inhalation and corticosteroid treatment. No
treatment-related death was observed.
DISCUSSION
In the present study, the MTDs of the combination
treatment of oral UFT and vinorelbine were determined, and
the activity and tolerability of the recommended dose of this
combination was assessed in elderly patients with locally
advanced or metastatic NSCLC.
In the development of new combination therapies for
malignant disease, it is essential to determine whether each
drug can interact additively or synergistically. In this regard,
we found in a previous study that sequential exposure to
vinorelbine followed by 5-FU showed additive or synergistic
activity against all three NSCLC cell lines tested in vitro.18
Additionally, in mice, treatment with vinorelbine before UFT
has been found to be associated with higher antitumor activ-
ity, lower toxicity, and longer survival than the reverse
sequence.18 On the basis of these preclinical data, we de-
signed an administration schedule under which vinorelbine
was infused on days 1 and 8, and UFT was administered on
days 2 to 6 and days 9 to 13 of a 3-week cycle.
The weekly administration of 20 to 25 mg/m2 vinorel-
bine and up to 600 mg/d UFT is approved in Japan, and
long-term administration of 400 mg/d UFT is standard in an
adjuvant setting for NSCLC.13 The most common DLT for
vinorelbine is leukocytopenia.23 For UFT as a single agent,
on the other hand, the most commonly experienced adverse
effect is gastrointestinal symptoms such as anorexia or nau-
sea. Leukocytopenia may occur but is mild even after long-
term administration of UFT as adjuvant chemotherapy.24,25
Judging that 400 mg/d UFT is not myelosuppressive, we
chose an initial dose of 20 mg/m2 vinorelbine and 400 mg/d
UFT (level I). We concluded that DLT during treatment with
the present drug regimen appears as severe neutropenia and
fever with neutropenia, that the MTD was level III (25 mg/m2
vinorelbine and 600 mg/d UFT), and that the recommended
tolerable dose for phase II trials is therefore dose level II (20
mg/m2 vinorelbine and 600 mg/d UFT).
In the phase II portion of the study, chemonaive elderly
patients with locally advanced or metastatic NSCLC were
treated with the recommended dose. This treatment achieved
an overall RR of 27% (8 PRs in 30 patients), a MST of 11.8
months, and a median progression-free survival time of 5.0
months.
There are some large-scale phase III studies in which
vinorelbine was administered to elderly patients with lung
cancer. Overall RR is reported to be 18 to 20% with 30
mg/m2 vinorelbine on days 1 and 8 in a 3-week cycle,6,26
whereas, in Japan, 25 mg/m2 vinorelbine achieved only 9.9%
RR.27 On the other hand, based on small-scale phase II
studies, UFT monotherapy exerted relatively low antitumor
activity of 6 to 9% RR in a usual lung cancer population.28–30
In vinorelbine-treated elderly patients with lung cancer, the
MST is 28 to 42 weeks.6,26,27 In the present phase II trial,
despite the low dose of vinorelbine (20 mg/m2) and the
TABLE 4. Toxicity in Phase II Study
Toxicity
NCI-CTC Grade
Grade 1 Grade 2 Grade 3 Grade 4
n % n % n % n %
Hematologic toxicity
Leukopenia 5 17 11 37 6 20 0 0
Neutropenia 2 7 8 27 9 30 3 10
Febrile neutropenia — — 2 7 0 0
Anemia 10 33 7 23 2 7 0 0
Thrombocytopenia 2 7 0 0 0 0 0 0
Nonhematologic toxicity
Increase in AST 0 0 1 3 0 0 0 0
Increase in ALT 0 0 1 3 0 0 0 0
Increase in Cr 0 0 1 3 0 0 0 0
Anorexia 15 50 4 13 0 0 0 0
Nausea 2 7 0 0 0 0 —
Constipation 6 20 3 10 1 3 0 0
Diarrhea 1 3 1 3 0 0 0 0
Mucositis 0 0 2 7 0 0 0 0
Taste disturbance 1 3 0 0 — —
Fatigue 7 23 0 0 0 0 0 0
Neuropathy 1 3 0 0 0 0 0 0
Injection site reaction 3 10 1 3 0 0 —
Pneumonitis 0 0 0 0 3 10 0
NCI-CTC, National Cancer Institute Common Toxicity Criteria; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Cr,
creatinine.
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intermittent administration of UFT (10 days in a 3-week
cycle), the RR of 27% and the median survival of 11.8
months are satisfactory, suggesting the synergistic interaction
of vinorelbine and UFT as observed in our preclinical inves-
tigation.18
Recently, Kudoh et al.27 reported that docetaxel (60
mg/m2 day 1 every 3 weeks) provided significantly longer
progression-free survival (5.5 months versus 3.1 months), a
significantly higher overall RR (22.7% versus 9.9%), a more
favorable MST (14.3 months versus 9.9 months), and signif-
icantly better disease-related symptom improvement than
vinorelbine (25 mg/m2 days 1 and 8, every 3 weeks) in
elderly patients with NSCLC. Although the MST of 11.8
months in this study was inferior to that of docetaxel mono-
therapy, the overall RR of 27% surpassed that of docetaxel. In
addition, despite high overall RR with cisplatin plus gemcit-
abine (43.3%) or vinorelbine (36.6%) in a phase II study
intended for elderly patients,31 the MST in this study was
more favorable than those of the cisplatin-based chemother-
apies (43.6 and 33.1 weeks, respectively). Accordingly, in
terms of efficacy, we propose that the combination of vinorel-
bine and UFT has positive potential in the treatment of
elderly patients with NSCLC.
With respect to toxicity, the combination of vinorelbine
and UFT was generally well tolerated even in elderly patients
with NSCLC. Hematologic toxicity such as neutropenia was
common. However, all patients recovered from this toxicity
promptly or after the permitted 7-day delay of a new cycle or
day-8 vinorelbine followed by UFT.
Gastrointestinal toxicity such as anorexia and constipa-
tion was the most common nonhematologic toxicity. Consti-
pation was mild and controlled with laxative administration.
The dose reduction of UFT from 600 to 400 mg/d alleviated
UFT-induced anorexia. Although 600 mg/d UFT was admin-
istered without variation in this phase II study, dose adjust-
ment of UFT may be necessary based on body surface area.
As an unexpected complication, pneumonitis was ob-
served in three patients of the phase II portion and one patient
of the phase I study. To our knowledge, pneumonitis has not
been reported as a major serious side effect of either vinorel-
bine or UFT in the literature. According to product docu-
ments of vinorelbine (Kyowa Hakko Kogyo Co., Japan) or
UFT (Taiho Pharmaceutical Co., Japan), the incidence of
pneumonitis because of vinorelbine and UFT is 1.4% and less
than 0.1%, respectively. In one of four patients, drug-induced
lymphocyte stimulation test for UFT was confirmed to be
positive, suggesting an incidental event in this case. Although
the pneumonitis observed in this study might be coincidental,
there is a possibility that this complication may be a combi-
nation-specific side effect, and this lung toxicity should be
assessed with caution when using this combination therapy.
In terms of the combination of UFT and vinorelbine,
the tolerable dose of both drugs may differ with race. The
activity of DPD that catabolizes 5-FU differs among various
ethnical groups.32 Weekly administration of 30 mg/m2 vi-
norelbine as a single agent is standard in Europe,5 whereas 25
mg/m2 vinorelbine is recommended in a Japanese popula-
tion.33 Accordingly, it may be necessary to determine the
optimal dose of this combination therapy based on race.
With respect to UFT-containing treatment for NSCLC,
several prognostic factors are proposed. In the combination of
UFT and gemcitabine, good PS, adenocarcinoma, and non-
smoking history can predict increased survival.17 The expres-
sion of thymidylate synthase, orotate phosphoribosyltrans-
ferase, and DPD in tumor are prognostic factors for the
survival of resected NSCLC patients postoperatively treated
with UFT.34,35 Therefore, the consideration of these factors
may lead to improved survival in the combination treatment
of UFT and vinorelbine.
In conclusion, this study defined the recommended
doses of combination chemotherapy with vinorelbine (20
mg/m2; d 1,8; intravenous) and UFT (600 mg/d; d 2–6, d
9–13; p.o.) in patients with advanced NSCLC. This combi-
nation therapy is both feasible and active in the treatment of
elderly patients with advanced NSCLC. The adverse effects
of this combination therapy that were found in the present
study were both tolerable and manageable. We propose that
this combination therapy can be an option for elderly patients
with NSCLC.
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